PERK inhibition with GSK2606414 in zebrafish evokes developmental defects consistent with Wolcott-Rallison syndrome phenotypes
L. M. Almeida, L. P. Lima, N. A. S. Oliveira, R. F. O. Silva, B. Sousa, J. Bessa, B. R. Pinho, J. M. A. Oliveira
This study uses zebrafish to model Wolcott-Rallison syndrome by inhibiting PERK with GSK2606414, revealing developmental defects consistent with the syndrome.
bioRxiv · Apr 16, 2024Pharmacology & Toxicology